FDA Clears First Growth-Adaptive Heart Valve for Children with Congenital Defects
Children born with certain congenital heart defects often face a difficult journey: synthetic heart valves placed during infancy are fixed in size, meaning patients must undergo multiple invasive surgeries as they outgrow each implant. The FDA has now approved a new artificial heart valve designed to address this long-standing challenge.
The device, called Autus, is a size-adjustable prosthetic heart valve that can be expanded non-surgically using a minimally invasive catheter-based procedure as the child grows. Unlike traditional mechanical or bioprosthetic valves, which require replacement surgeries each time a child outgrows them, the Autus valve allows physicians to upsize the valve without additional open-heart operations.
This approval marks a significant advancement in pediatric cardiac care. Repeated open-heart surgeries carry substantial risks including infection, extended recovery times, and cumulative trauma to young bodies. By reducing the number of surgeries required, the technology aims to improve both long-term outcomes and quality of life for affected children and their families.
The valve received approval based on clinical data demonstrating its safety and effectiveness in pediatric patients requiring valve replacement. Developers worked closely with pediatric cardiothoracic surgeons and interventional cardiologists throughout the design and testing process to ensure the device meets the unique anatomical and physiological needs of growing hearts.